Erlotinib in Combination With Pralatrexate in Advanced Malignancies

Summary

The goal of this clinical research study is to find the highest tolerable dose of the combination of erlotinib and pralatrexate that can be given to patients with advanced cancer. The safety of the drug combination will also be studied. Pralatrexate is designed to block the body's ability to make folic acid, a protein that may help cancer tissue to develop and spread. Erlotinib hydrochloride is designed to block proteins that are thought to cause cancer cells to grow. Erlotinib may help slow the growth of tumors.

Timeline

Start

2012-03

Primary completion

2016-06

Completion

2016-06

Drugs

Indications